GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004339327 | Thyroid | ATC | regulation of protein binding | 110/6293 | 196/18723 | 6.99e-11 | 2.22e-09 | 110 |
GO:006082825 | Thyroid | ATC | regulation of canonical Wnt signaling pathway | 134/6293 | 253/18723 | 1.49e-10 | 4.56e-09 | 134 |
GO:006007025 | Thyroid | ATC | canonical Wnt signaling pathway | 154/6293 | 303/18723 | 3.68e-10 | 1.02e-08 | 154 |
GO:000164932 | Thyroid | ATC | osteoblast differentiation | 122/6293 | 229/18723 | 6.04e-10 | 1.60e-08 | 122 |
GO:006056222 | Thyroid | ATC | epithelial tube morphogenesis | 156/6293 | 325/18723 | 4.48e-08 | 8.14e-07 | 156 |
GO:003209224 | Thyroid | ATC | positive regulation of protein binding | 53/6293 | 85/18723 | 5.37e-08 | 9.67e-07 | 53 |
GO:000184119 | Thyroid | ATC | neural tube formation | 59/6293 | 102/18723 | 4.28e-07 | 6.25e-06 | 59 |
GO:002191515 | Thyroid | ATC | neural tube development | 80/6293 | 152/18723 | 9.87e-07 | 1.29e-05 | 80 |
GO:000183823 | Thyroid | ATC | embryonic epithelial tube formation | 65/6293 | 121/18723 | 4.02e-06 | 4.43e-05 | 65 |
GO:001402017 | Thyroid | ATC | primary neural tube formation | 53/6293 | 94/18723 | 4.69e-06 | 5.11e-05 | 53 |
GO:000184316 | Thyroid | ATC | neural tube closure | 50/6293 | 88/18723 | 6.43e-06 | 6.68e-05 | 50 |
GO:003017815 | Thyroid | ATC | negative regulation of Wnt signaling pathway | 85/6293 | 170/18723 | 6.94e-06 | 7.16e-05 | 85 |
GO:006060616 | Thyroid | ATC | tube closure | 50/6293 | 89/18723 | 9.90e-06 | 9.87e-05 | 50 |
GO:007217522 | Thyroid | ATC | epithelial tube formation | 68/6293 | 132/18723 | 1.59e-05 | 1.48e-04 | 68 |
GO:001633114 | Thyroid | ATC | morphogenesis of embryonic epithelium | 74/6293 | 147/18723 | 1.96e-05 | 1.77e-04 | 74 |
GO:003514823 | Thyroid | ATC | tube formation | 74/6293 | 148/18723 | 2.65e-05 | 2.27e-04 | 74 |
GO:004566721 | Thyroid | ATC | regulation of osteoblast differentiation | 66/6293 | 132/18723 | 7.03e-05 | 5.36e-04 | 66 |
GO:004566912 | Thyroid | ATC | positive regulation of osteoblast differentiation | 38/6293 | 69/18723 | 1.97e-04 | 1.31e-03 | 38 |
GO:009009014 | Thyroid | ATC | negative regulation of canonical Wnt signaling pathway | 66/6293 | 137/18723 | 2.82e-04 | 1.80e-03 | 66 |
GO:00487715 | Thyroid | ATC | tissue remodeling | 78/6293 | 175/18723 | 1.60e-03 | 8.04e-03 | 78 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00270 | Liver | Cirrhotic | Cysteine and methionine metabolism | 27/2530 | 52/8465 | 6.98e-04 | 4.15e-03 | 2.56e-03 | 27 |
hsa00260 | Liver | Cirrhotic | Glycine, serine and threonine metabolism | 22/2530 | 40/8465 | 7.85e-04 | 4.51e-03 | 2.78e-03 | 22 |
hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa002701 | Liver | Cirrhotic | Cysteine and methionine metabolism | 27/2530 | 52/8465 | 6.98e-04 | 4.15e-03 | 2.56e-03 | 27 |
hsa002601 | Liver | Cirrhotic | Glycine, serine and threonine metabolism | 22/2530 | 40/8465 | 7.85e-04 | 4.51e-03 | 2.78e-03 | 22 |
hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0123021 | Liver | HCC | Biosynthesis of amino acids | 53/4020 | 75/8465 | 3.79e-05 | 2.11e-04 | 1.18e-04 | 53 |
hsa002702 | Liver | HCC | Cysteine and methionine metabolism | 35/4020 | 52/8465 | 3.03e-03 | 9.94e-03 | 5.53e-03 | 35 |
hsa002602 | Liver | HCC | Glycine, serine and threonine metabolism | 28/4020 | 40/8465 | 3.28e-03 | 1.07e-02 | 5.93e-03 | 28 |
hsa0123031 | Liver | HCC | Biosynthesis of amino acids | 53/4020 | 75/8465 | 3.79e-05 | 2.11e-04 | 1.18e-04 | 53 |
hsa002703 | Liver | HCC | Cysteine and methionine metabolism | 35/4020 | 52/8465 | 3.03e-03 | 9.94e-03 | 5.53e-03 | 35 |
hsa002603 | Liver | HCC | Glycine, serine and threonine metabolism | 28/4020 | 40/8465 | 3.28e-03 | 1.07e-02 | 5.93e-03 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTH | SNV | Missense_Mutation | | c.592N>A | p.Pro198Thr | p.P198T | P32929 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CTH | SNV | Missense_Mutation | novel | c.598N>T | p.Ala200Ser | p.A200S | P32929 | protein_coding | tolerated(0.67) | benign(0) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CTH | insertion | Frame_Shift_Ins | novel | c.1119_1120insCTAGTTTTTTCAAAGC | p.Ile374LeufsTer15 | p.I374Lfs*15 | P32929 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
CTH | insertion | Frame_Shift_Ins | novel | c.1121_1122insCAGAGGATATTGGTACAAGAAGCAG | p.Leu376GlyfsTer16 | p.L376Gfs*16 | P32929 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
CTH | SNV | Missense_Mutation | rs866702899 | c.469G>A | p.Glu157Lys | p.E157K | P32929 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CTH | SNV | Missense_Mutation | novel | c.979N>C | p.Ile327Leu | p.I327L | P32929 | protein_coding | tolerated(0.23) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
CTH | SNV | Missense_Mutation | | c.241N>A | p.Ala81Thr | p.A81T | P32929 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CTH | SNV | Missense_Mutation | novel | c.1124N>A | p.Arg375Gln | p.R375Q | P32929 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
CTH | SNV | Missense_Mutation | novel | c.626N>A | p.Ser209Tyr | p.S209Y | P32929 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTH | SNV | Missense_Mutation | novel | c.1177N>A | p.Ala393Thr | p.A393T | P32929 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |